In Brief: FDA FY 1999 goals
This article was originally published in The Tan Sheet
Executive Summary
FDA FY 1999 goals: Public reports from the Special Nutritionals Adverse Events Monitoring System will at least double in 1999 from the current two per year, FDA says in its FY 1999 budget justification. The agency notes it will "continue to respond to safety concerns associated with the rapidly expanding use and misuse of dietary supplement products such as ephedra." Regarding OTCs, FDA expresses its commitment to improving "the legibility and clarity of OTC drug labels" and "the consumer's ability to read and understand important warnings and usage directions." The President's budget request for FDA was issued Feb. 2 ("The Tan Sheet" Feb. 9, p. 15)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning